Macrocure names Nissim Mashiach CEO
This article was originally published in Clinica
Executive Summary
Macrocure, a biotech specialising in cell therapy for hard-to-heal wounds, has appointed Nissim Mashiach president and CEO. Mr Mashiach most recently served as general manager at Ethicon, a Johnson & Johnson company. Prior to that, he was president and COO at Omrix Biopharmaceuticals, a company acquired by J&J for $438m in 2008 (www.clinica.co.uk, 22 December 2008).